Unternehmensübersicht
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on the development and commercialization of orally bioavailable small molecule therapeutic products. The company's strategic scope encompasses the treatment of specific medical conditions including cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. Positioned within the broader Healthcare sector and the specialized Biotechnology industry, the firm targets high-value therapeutic areas requiring significant research and development investment. The company maintains a market capitalization of $7.23M and generates annual revenue of $405,000, employing a workforce of five individuals. These valuation and revenue figures indicate that Can-Fite BioPharma is a micro-cap entity operating with limited financial resources, characteristic of early-stage biotech firms that prioritize asset accumulation and clinical progress over immediate profitability.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $405,000, yet it recorded a net income of $-9,828,000 and an EBITDA of $-9,926,000 for the same period. The substantial disparity between the minimal revenue generation and the multi-million dollar net loss highlights a cost structure dominated by high burn rates typical of clinical-stage development, where expenses for research, personnel, and regulatory compliance vastly outweigh sales income. Free cash flow stood at $-4,985,750, indicating a continuous cash outflow that necessitates reliance on external financing or existing cash reserves to sustain operations. Gross margin is recorded at 100.0%, reflecting a cost of goods sold of zero, which is common for pre-revenue companies, while the operating margin of -2488.7% and profit margin of 0.0% underscore the severe operational inefficiencies relative to sales volume at this developmental stage. The balance sheet holds $8.54M in cash against $71,000 in debt, resulting in a debt-to-equity ratio of 1.27, which suggests a leveraged position despite the low absolute debt amount due to the equity base size. A current ratio of 3.46 demonstrates strong short-term liquidity, as the company possesses more than three times the current assets needed to cover its current liabilities. Return on equity is -178.2% and return on assets is -66.7%, metrics that reveal that management has not yet achieved profitability and that the capital base is generating negative returns on investment.
Bewertungsanalyse
The trailing P/E ratio is N/A due to the lack of positive net income, while the forward P/E stands at -4.22, a negative metric that implies earnings are projected to remain negative or that the denominator is mathematically distorted by losses. The price-to-book ratio is 1.44, indicating that the market values the company at approximately 44% above its tangible book value, a premium often associated with intangible assets like intellectual property or potential clinical trial success. The price-to-sales ratio is 17.85 and the EV/EBITDA is -0.48, suggesting that valuing the company through traditional multiple expansion models is less reliable given the negative earnings and high revenue multiple compression relative to sales volume. Over the past year, the stock has traded between a 52-week low of $2.95 and a 52-week high of $36.40. Without the specific current share price listed in the provided facts, the exact percentage deviation from these bounds cannot be calculated, but the wide trading range of over $33.00 signifies significant price volatility within a single fiscal year. The beta value is -0.10, a unique and highly unusual metric that technically implies an inverse correlation to the broader market, though such a figure often suggests data anomalies or extreme idiosyncratic risk rather than standard market sensitivity.
Growth & Income
Revenue growth year-over-year is recorded at -43.3%, while earnings growth is N/A due to the company's continuous losses. The decline in revenue indicates a contraction in sales or a reduction in the sales force's ability to commercialize the drug candidates, while the absence of earnings growth data reflects the inherent instability of pre-profit biotech firms. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning no cash is distributed to shareholders. Consequently, the firm reinvests all available liquidity and retained earnings into ongoing research and development efforts rather than returning capital to the equity base. The overall growth and income profile is characterized by negative revenue momentum, significant cash consumption, and a total absence of income distribution, reflecting a high-risk investment thesis centered entirely on future clinical milestones rather than current financial performance.